Is there balm in Gilead?
Article Abstract:
Biotech company shares, especially anti-infective companies' shares are good options for investors interested in buying pharma shares. Though, some shares like Gilead might be over valued presently, in the long-term Gilead could be a good option but one has to keep watch and be patient.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
Paying over the odds
Article Abstract:
Investors, in their inability to evaluate valuation risk, often lose money by overpaying for growth or failing to sell when the growth does not warrant the valuation. A way to evaluate valuation risk is provided along with a prominent biotech example.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Asia's other tiger. War on poverty rages on
- Abstracts: Full steam ahead. Risk and reward. When rates tighten up
- Abstracts: Further cuts may loom in Navy shipbuilding request. . Costs loom for Northrop, others in storm damage. Northrop Ship Systems yard braced for hurricane
- Abstracts: Richard Jefferson. Struggling to see the forest through the trees. Jim Greenwood
- Abstracts: Overhauling clinical trials. Anti-infective antibodies: Finding the path forward. Better living through microbes